Uncategorized

In recent years, with the rapid development of immunotherapeutic agents such as bispecific antibodies, the treatment landscape of acute lymphoblastic leukemia has entered a new era of hope. At the…

 Immunotherapy has fundamentally reshaped the treatment landscape of gastrointestinal (GI) cancers. However, now that PD-1/PD-L1 inhibitors have been firmly established as standards of care, the key challenge facing clinical research is how to further overcome the current efficacy plateau. This has driven research into a “deep-water zone,” where novel strategies—such as next-generation TIGIT inhibitors, cancer vaccines, and T-cell engagers—are actively being explored.

From November 6–9, 2025, the 2025 China Conference on Holistic Integrative Oncology (CCHIO) was held in Kunming. As one of the most influential oncology conferences in China, CCHIO gathered leading…

&feature=youtu.be

Acute promyelocytic leukemia (APL) is among the most curable forms of pediatric acute myeloid leukemia, primarily due to the success of ATRA and arsenic trioxide (ATO)-based therapies. However, the contribution of cytarabine (Ara-C) to long-term outcomes remains debated. In this newly published study in Blood Science, researchers present the results of a prospective, randomized trial examining the long-term impact of adding Ara-C during consolidation therapy for children with APL.

Cutaneous T-cell lymphoma (CTCL) is a heterogeneous malignant lymphoma originating from the skin and evolving from T-cells. It accounts for approximately 4% of non-Hodgkin lymphoma cases, classifying it as a…

Editor’s Note:The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of the…

We were honored to hear from Professor Xiaojun Huang of Peking University People’s Hospital and the Peking University Institute of Hematology, who shared a comprehensive reflection on the global evolution of hematopoietic stem cell transplantation (HSCT). From Dr. Edward Donnall Thomas' foundational work to the creation of the Beijing Protocol, Professor Huang spotlighted how China’s innovations—including non–T-cell-depleted haploidentical transplantation—are transforming clinical practice worldwide.